Document Detail


Determination of the anti-ischemic activity of nebivolol in comparison with atenolol.
MedLine Citation:
PMID:  7910155     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The anti-ischemic effect of 5 mg nebivolol o.i.d., a newly developed beta 1-selective adrenoceptor blocking drug with vasodilating properties, was compared with that of atenolol (100 mg o.i.d.) following a treatment period of 6 days. The study was performed in 24 patients with documented coronary artery disease and stable angina pectoris according to a double-blind randomized study, designed using conventional symptom-limited exercise testing. Exercise testing 3 h after the first dose showed a more marked ST-segment reduction by atenolol than by nebivolol (59% vs. 18%). ST-segment depression measured 24 h after administration of the penultimate dose was statistically significantly reduced by nebivolol (from 0.19 +/- 0.07 to 0.13 +/- 0.07 mV; P = 0.0059) but not by atenolol (from 0.17 +/- 0.06 to 0.14 +/- 0.10 mV; P = 0.0703). Approximately 3 h after the last dose, the reduction was comparable (45% and 38% by nebivolol and atenolol, respectively). Exercise duration, exercise time necessary to produce ST-segment depression by 0.1 mV and exercise time to the onset of angina were also prolonged following administration of both drugs. Thus, at steady-state single daily doses of 100 mg atenolol and 5 mg nebivolol were about equieffective when measured at time of maximal effect (i.e. 3 h after drug administration). However, duration of action with respect to the ST-segment depression seems to be slightly longer for nebivolol.
Authors:
G Ruf; D Trenk; E Jähnchen; H Roskamm
Related Documents :
21374645 - Hsp70 expression: does it a novel fatigue signalling factor from immune system to the b...
22871905 - Feasibility and perception of the impact from aerobic exercise in older adults with alz...
1479305 - The natural course of clostridium perfringens--induced pneumatosis cystoides intestinalis.
12620995 - Exercise-induced electrocardiographic changes in patients with chronic respiratory dise...
10805885 - Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect i...
3310565 - Acute and chronic hemodynamic effects of nicardipine hydrochloride in patients with hea...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  International journal of cardiology     Volume:  43     ISSN:  0167-5273     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  1994 Mar 
Date Detail:
Created Date:  1994-06-16     Completed Date:  1994-06-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  279-85     Citation Subset:  IM    
Affiliation:
Abteilung für Klinische Pharmakologie, Benedikt Kreutz Rehabilitationszentrum, Bad Krozingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / adverse effects,  blood,  therapeutic use*
Adult
Aged
Angina Pectoris / physiopathology,  prevention & control
Atenolol / adverse effects,  blood,  therapeutic use*
Benzopyrans / adverse effects,  blood,  therapeutic use*
Blood Pressure / drug effects
Coronary Disease / complications*,  physiopathology
Double-Blind Method
Electrocardiography / drug effects
Ethanolamines / adverse effects,  blood,  therapeutic use*
Exercise Test
Female
Heart Rate / drug effects
Humans
Male
Middle Aged
Myocardial Ischemia / prevention & control*
Vasodilator Agents / adverse effects,  blood,  therapeutic use*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Benzopyrans; 0/Ethanolamines; 0/Vasodilator Agents; 29122-68-7/Atenolol; 99200-09-6/nebivolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Doxorubicin retention and chemoresistance in human mesothelioma cell lines.
Next Document:  Behavioral group therapy with obsessive-compulsives: an overview.